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Abstract: In the context of glucocorticoid (GC) therapeutics, recent studies have utilised a subcuta-
neous hydrocortisone (HC) infusion pump programmed to deliver multiple HC pulses throughout
the day, with the purpose of restoring normal circadian and ultradian GC rhythmicity. A key chal-
lenge for the advancement of novel HC replacement therapies is the calibration of infusion pumps
against cortisol levels measured in blood. However, repeated blood sampling sessions are enor-
mously labour-intensive for both examiners and examinees. These sessions also have a cost, are time
consuming and are occasionally unfeasible. To address this, we developed a pharmacokinetic model
approximating the values of plasma cortisol levels at any point of the day from a limited number
of plasma cortisol measurements. The model was validated using the plasma cortisol profiles of
9 subjects with disrupted endogenous GC synthetic capacity. The model accurately predicted plasma
cortisol levels (mean absolute percentage error of 14%) when only four plasma cortisol measurements
were provided. Although our model did not predict GC dynamics when HC was administered in a
way other than subcutaneously or in individuals whose endogenous capacity to produce GCs is intact,
it was found to successfully be used to support clinical trials (or practice) involving subcutaneous
HC delivery in patients with reduced endogenous capacity to synthesize GCs.
Keywords: glucocorticoid pulsatility; pharmacokinetic model; subcutaneous delivery; glucocorticoid
insufficiency; hydrocortisone replacement therapy
1. Introduction
Glucocorticoids (GCs) are a class of steroid hormones naturally secreted by the adrenal
glands of mammals. They rapidly diffuse via the bloodstream across the body, modulating
multiple physiological systems, e.g., metabolism, the immune system, the nervous system,
as well as under baseline and stressful conditions [1]. Due to their lipophilic nature, GCs
move freely across extracellular and intracellular membranes and bind to two classes of
GC-sensitive receptors: glucocorticoid receptors (GRs) and mineralocorticoid receptors
(MRs) [2]. Binding events between the hormone and its receptors induce rapid, non-
genomic activity of molecular signalling cascades (involving activation and inhibition of
second messenger molecules such as the cyclic adenosine monophosphate) [3] as well as
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delayed, genomic phenomena (activation and inhibition of gene expression after interacting
with GC-responsive elements) [4]. The plethora of different cellular responses to GC
stimulation is particularly evident in the brain, where both major receptor types (GRs and MRs)
are exposed to GCs. In other tissues, such as the kidneys, the presence of 11β-hydroxysteroid
dehydrogenase 2 in the proximity of MR- and GR-expressing cells deactivates GCs, which
prevents binding to GC-sensitive receptors [5].
For any brain region containing different numbers of neurons and glial cells and
expressing different distributions of GRs and MRs, the type of cellular responses to GCs
can be understood as a complex interplay between: (i) the concentration of the hormone in
the microenvironment of that brain region and (ii) the duration of the hormonal presence in
that region. For instance, when GCs are in abundance, GRs can rapidly (i.e., within seconds)
be activated by GCs and subsequently bind to chromatin. However, at each of these
exchange events, when GC levels fall, there is an increased probability that the hormone
ligand will be lost from the GR; unbound GR will then either be metabolized by nuclear or
cytoplasmic proteosome or enter the chaperone cycle, with the association of the molecular
chaperones HSP90 and p23. In this state, the GR (and other transcriptional cofactors) are
not associated with chromatin, and the histone acetylation state returns rapidly to basal
levels [6,7]. Moreover, the binding affinities of GCs for MRs are much higher compared
to GRs—i.e., lower levels of GCs are required to induce MR-dependent effects, whereas
GR-dependent effects require higher GC levels [8]. Finally, prolonged exposure to high GC
levels leads to downregulation of GR expression in the brain [9]. These examples indicate
how important the dynamic regulation of GC levels in the microenvironment of brain cells
is for determining the type of cellular responses to GC stimulation.
The delayed negative feedback loop between the control centre of GC biosynthesis
(anterior pituitary) and the GC-producing tissue (adrenal gland cortex) creates a natural,
ultradian rhythm of GC secretion [10]. This ultradian rhythm consists of periodic bursts
of GC biosynthesis and then releases into the systemic circulation, which rapidly travels
across the body (95% of which is bound to carrier proteins of the blood stream). Thus, under
baseline conditions, GC-sensitive tissues (such as the brain) are exposed to short-lasting GC
pulses, wherein periods of high GC levels (potentially inducing genomic and non-genomic
GR-dependent and non-genomic MR-dependent effects) alternate with periods of low GC
levels (crucial for resetting the afore-mentioned molecular mechanisms, i.e., sustain their
sensitivity to a forthcoming GC pulse) [11]. The ultradian GC rhythm is not only significant
from a physiological point of view but also from a pharmacological perspective: current GC
replacement therapy does not reproduce the characteristics of complex physiological GC
rhythms, leading to suboptimal treatment of patients with adrenocortical insufficiency [12].
In recent years, we conducted two clinical trials to investigate the neurobiological
significance of the ultradian GC rhythm in humans, either healthy volunteers [13,14] or
patients with adrenocortical insufficiency. The trial in the latter case [15] aimed at altering
the HC dosing regimen to restore physiological ultradian hormonal rhythmicity. These
studies were the first to show that something closer to physiological HC delivery might
improve brain function in patients and offer a better self-perceived sense of well-being and
quality of life. In both studies, we used a novel pump of sub-cutaneous HC delivery (Crono
P®, CANE Applied Medical Technology Ltd., Cambridge, UK), programmed to deliver
8 HC pulses every three hours at a rate of 10 µL/s [14], and in particular 400 µL solution
(containing 4 mg of hydrocortisone) at 03:00 a.m., 06:00 a.m. and 09:00 a.m., 230 µL solution
(containing 2.3 mg of hydrocortisone) at 12:00 p.m., 15:00 p.m., and 18:00 p.m., and 50 µL
solution (containing 0.5 mg of hydrocortisone) at 21:00 p.m. and midnight. A preliminary
validation study preceded these trials to verify that pharmacological interventions involv-
ing the Crono P®-mediated HC delivery could achieve the desired GC dynamics in the
blood stream [16].
The dynamics of GCs in the systemic circulation created by the Crono P® under differ-
ent settings has been previously monitored through daily blood sampling sessions with
a 10 min sampling rate, as well as a subsequent determination of plasma cortisol levels.
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However, this process is enormously labour-intensive for both examiners and examinees
and its feasibility is questionable under certain experimental settings (e.g., multimodal neu-
roimaging studies that can take up to two hours, including preparation of the participants,
potential cognitive training, scanning and/or neurofeedback session). Thus, the aim of
this work is to provide a mathematical model that describes the pharmacokinetics of the
subcutaneous delivery of HC doses through the Crono P®. We show how this model can
be used to approximate the values of plasma cortisol levels at any time point of the day
using only a limited number of plasma cortisol measurements as model inputs.
2. Results
2.1. HC Delivery Assuming Constant Absorption and Clearance Rates
For this part of the study, we used the 24-h plasma cortisol profile of Subject 1 from
the Pulses study (see Materials and Methods). First, we fitted the model parameters k and
kα using the initial 3 h of data (Figure 1a). If we continue the model simulations for the
next 6 h of data using these rates, the model predictions diverge from the measured levels
of plasma cortisol (Figure 1b).
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the model fitting to data over 24 h (Figure 2). However, this is not an adequate process for 
a predictive model with minimal input. 
Figure 1. athematical model predictions of plasma cortisol levels assuming constant absorption
(kα) and secretion (k) rates. The model fits the data during the first three hours (a), but for the
estimated (k, kα) values, it significantly deviates fro the observed plasma cortisol values past the
first three hours (b). Plasma cortisol measurements belong to Subject 1 from the Pulses study (see
aterials and Methods). CORT: cortisol.
2.2. HC Delivery Assuming Piecewise Absorption and Clearance Rates That Change Every 3 h
To improve the output of the model for longer time intervals (using the 24-h plasma
cortisol data of Subject 1 from the Pulses study), we needed to recalibrate the absorption
and clearance rates every 3 h. This piecewise adjustment of model parameters improves
the model fitting to data over 24 h (Figure 2). However, this is not an adequate process for
a predictive model with minimal input.
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every 3 h. Specifically, we used the model to produce a curve for every 3-h interval, which was then fitted to data with
different (k, kα) pairs for each curve. Then, we concatenated the curves creating a piecewise fitted simulation with a
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error was estimated to be 14%. 
Figure 3. Simulation of plasma cortiso changes in different healthy subjects with pharmacologically suppressed cortisol
biosynthesis with dexamethasone (see Materials and Methods) after the subcutaneous infusion of varying doses of
hydrocortisone. The simulations were produced by the revised model (see Materials and Methods), which assumes
discretely varying absorption and secretion rates of cortisol. (a) female subject, BMI: 20.4, pulse time: 10:00 a.m., pulse
volume (D): 30 µL (0.3 mg); (b) male subject, BMI: 30, pulse time: 10:00 a.m., pulse volume (D): 150 µL (1.5 mg); (c) male
subject, BMI: 22.5, pulse time: 10:30 a.m., pulse volume (D): 200 µL (2 mg); (d) male subject, BMI: 21.2, pulse time: 09:50 a.m.,
pulse volume (D): 350 µL (3.5 mg), (e) male subject, BMI: 23.3, pulse time: 10:10 a.m., pulse volume (D): 350 µL (3.5 mg);
(f) female subject, BMI: 23.4, pulse time: 09:50 a.m., pulse volume (D): 400 µL (4 mg); BMI: body-mass index, CORT: cortisol,
D: dose.
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Figure 4. Assuming discretely varying absorption and clearance rates (revised model), the brute-force
search method provides the initial pair of (k0, kα0), based on four CORT measurements (e.g., at
time points 0, 30, 60 and 90 min), and subsequently estimates the whole 24-h profile of plasma
cortisol. The data from the Pulses study Subject 1 was used (see Materials and Methods). CORT:
cortisol, k: clearance rate, kα: absorption rate. Time points of delivery (magnitude of doses): 0 min
(2.3 mg/230 µL), 180 min (2.3 mg/230 µL), 360 min (0.5 mg/50 µL), 540 min (0.5 mg/50 µL), 720 min
(4 mg/400 µL), 900 min (4 mg/400 µL), 1080 min (4 mg/400 µL), 1260 min (2.3 mg/230 µL).
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2.4. Validation of the Optimised Model for HC Delivery
The revised assumptions enabled the model to estimate plasma cortisol data through
a simple and easy to use algorithm requiring only four data points as inputs. To validate
our approach, we predicted the 24-h cortisol profile from the remaining two participants
from the Pulses study (Figure 5). We did this by calculating the corresponding single pair
of (k0, kα0) rates from only four plasma cortisol values measured at time points 0, 30 min,
60 min and 90 min. We also estimated the magnitude of the relative error for every time
point of the model predictions versus the plasma cortisol data. Finally, the mean absolute
error was estimated to be 14%.
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Figure 5. (a) Comparison of the revised model predictions (yellow line) with the ultradian rhythm of plasma cortisol
observed in subject 2 (blue dots) from the Pulses study following subcutaneous pulsatile CORT infusion (see Materials
and Methods). (b) Comparison of the revised model predictions (yellow line) with the ultradian rhythm of plasma cortisol
observed in subjects 3 (blue dots) from the Pulses study following subcutaneous pulsatile CORT infusion (see Materials and
Methods). The revised mo el assumes discretely varying absorption and cle ran e rates and the brut-force search method
calculates the initial pa r of (k0, kα0) rates by four cortisol measure nts (for instance at timepoints 0, 30 60 and 9 min). We
also estimated the relative error of the model predictions across all plasma cortisol data points for subject 2 (c) and 3 (d). The
periodicity of the data allows us to assume that the value of cortisol 24 h later is the same as the first value given, and hence,
the error is reduced as we approach the end of that 24-h period. CORT: cortisol, k: clearance rate, kα: absorption rate. Time
points of delivery (magnitude of doses): 0 min (2.3 mg/230 µL), 180 min (2.3 mg/230 µL), 360 min (0.5 mg/50 µL), 540 min
(0.5 mg/50 µL), 720 min (4 mg/400 µL), 900 min (4 mg/400 µL), 1080 min (4 mg/400 µL), 1260 min (2.3 mg/230 µL).
2.5. Reaches and Limitations of the Model
A question that naturally arises is what is the best possible fit that our model can
achieve. The process of finding this is straightforward given the following functions:












Mi(t) is the i-th measurement taken every 10 intervals. We defined the error function for
any n measurements as follows:
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especially relevant to hormonal replacement therapies.
For the last 15 years, the scientific community has gathered multiple complementary
pieces of evidence that support the notion that glucocorticoid pulsatility has biological
significance [18], and thus chronopharmacological aspects in therapeutics involving glu-
cocorticoids should be taken into serious consideration. In this context, pump-mediated
glucocorticoid replacement strategies can replicate fast hormone secretion dynamics, thus
offering certain advantages over other treatment approaches that disregard ultradian hor-
mone pulsatility (e.g., oral substitution of HC twice or thrice daily or a pump-mediated
continuous HC replacement).
Our group examined the scientific potential and challenges of pump-mediated dy-
namic hormone infusion through a series of clinical trials [13,16,19,20]. In these trials, either
healthy volunteers with a pharmacologically disrupted capacity to produce glucocorticoids
or patients with adrenocortical insufficiency underwent a pulsatile scheme of subcutaneous
HC replacement. In the case of patients, this involved the daily infusion of 8 pulses of HC
every 3 h, with varying doses depending on the time of the day. In these studies, patients
were required to remain hospitalized for at least 24 h, while repeated blood samples were
collected throughout the day. This continuous sampling allowed us to construct their
daily plasma cortisol profile, and thus verify whether the pump-mediated treatment was
replicating the desired hormonal dynamic pattern.
In this paper, we postulated a mathematical model that describes the pharmacokinetics
of cortisol administration in adrenocortical insufficiency patients. We show how the model
can be used to calibrate pump-mediated HC replacement, a necessary step for its adoption
in clinical practice. Further, we presented an automated process to recalibrate the pump
that optimizes plasma cortisol delivery for any individual given only four single time
point measurements of plasma cortisol. In general, our model shows a reasonable accuracy
(mean absolute percent error of 14%) in predicting 24 h long hormone profiles measured in
patients (Figure 5). For smaller periods of time, the model accuracy can improve notoriously
as seen from the simulations that lasted for 3 h (Figure 3). It is expected that small errors in
our parameter estimations would invalidate the model predictions for long periods of time.
Yet our model can give a good estimate for the pharmacokinetics of cortisol replacement in
pump-mediated clinical trials that last up to 24 h.
Mathematical modelling can also shed light on our understanding of the physiological
mechanisms underlying the dynamic absorption and clearance of subcutaneous HC. While
both rates are likely to depend on individual differences (such as body mass index), our
model suggests that the clearance rate varies throughout the day. During our model
recalibration, we found the clearance can be affected by baseline levels of cortisol already
in the bloodstream, while at the same time the rate of absorption seems to drop the more
HC it is administered. The estimated rate of cortisol clearance is well within the predicted
variability observed in previous studies [21]. It should also be noted that, while k can
vary wildly among individuals, our model suggests that kα variability arises less from
individual differences and depends more on the given HC dose. On the other hand, the
optimised model relies on the assumption that although the absorption and clearance rates
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change over time, these changes are discontinuous and therefore the constant rate model is
a good approximation for small intervals of time. The algorithm used to estimate the initial
(k, kα) rates performs better when the input data points lie within a 30–40-min range, when
they are associated to low cortisol levels and when at least one local maxima of the plasma
cortisol profile is included. Similarly, the algorithm assumes that after 24 h the cortisol
levels must return to a value close to the initial data point. This considerably minimises the
error for the last 3 h of simulation. In general, the highest error is observed the further the
distance from the initial data points and before the last 6 h of the 24-h period (i.e., at the
interval from the 6-th to the 18-th hour from the beginning of the simulation).
Lastly, it is important to highlight that our model cannot predict plasma cortisol
pulsatility if HC is administered in ways other than subcutaneously, or in individuals
whose endogenous capacity to produce glucocorticoids is intact. This is because the
well-defined subcutaneous infusion scheme would be confounded–both dynamically and
quantitatively, with endogenous bursts of glucocorticoid secretion (affected by individual
differences in lifestyle, gene expression, and experience of stressful events). The model may
be solely used to predict and calibrate the pharmacokinetics of subcutaneous HC infusions
in individuals with impaired endogenous steroidogenic capacity.
4. Materials and Methods
4.1. Participants and Interventions
We extracted plasma cortisol data from clinical trials performed at the University of
Bristol (UK) over the past 7 years. These trials were performed in accordance with the
highest bioethical and local institutional provisions, under the approval of the Medicines
and Healthcare Products Regulatory Authority and according to the principles of Good
Clinical Practice and the Declaration of Helsinki. These studies recruited: (1) patients
with adrenocortical insufficiency (Addison’s disease and congenital adrenal hyperplasia)
(Pulses study, IRAS ID: 98045, EudraCT No: 2012-001104-37, ISRCTN67193733), and (2)
healthy volunteers whose endogenous cortisol secretion was suppressed via dexametha-
sone administration (IRAS ID: 106181, UKCRN-ID-15236). In the latter case, 1 mg of
dexamethasone was received orally by healthy volunteers at midnight at their home, and
1 mg was administered at 9 a.m. the next day at the research unit, prior to the experiment.
During the experiment, volunteers received two subcutaneous infusions of HC (via CANE
pump, see below) at varying time intervals and doses (dose range 0.3–4 mg) over a 7-h
period [16]. The first 3 h of plasma cortisol data following the first HC pulse were used
in this study. In the case of patients with adrenocortical insufficiency, HC replacement
therapy was administered over the course of 24 h in the same way (subcutaneously via
the CANE pump, see below), but distributed in 8 pulses (i.e., doses) with a constant 3 h
inter-pulse interval and three different dose amplitudes, a high dose (4 mg) at 03:00 a.m.,
06:00 a.m. and 09:00 a.m., an intermediate dose (2.3 mg) at midday, 03:00 p.m. and 06:00
p.m. and a small dose (0.5 mg) at 09:00 p.m. and midnight [13].
4.2. Technical Specifications of Subcutaneous Hydrocortisone Delivery
A portable subcutaneous infusion pump (Crono P, CANE Applied Medical Technology
Ltd., Cambridge, UK) containing 100 mg of HC in 1 mL (Efcortesol®; Sovereign Medical
Ltd., Stansted, Essex, UK) was made up to 10 mL with 0.9% saline and programmed to
deliver a high-, medium- and low-sized pulse of HC. All pulses were delivered at a flow rate
of 10 µL/s. The pump delivered HC subcutaneously via a cannula (Medtronic quick-set®,
Medtronic MiniMed, Northridge, CA, USA) inserted into the abdominal subcutaneous
tissue.
4.3. Acquisition of Plasma Cortisol Data
During the experimental process, blood samples were collected via an intravenous
cannula every 10 min for serum cortisol concentration estimation. Blood sampling was
being performed by the human automated blood sampler (HABS) [19]. The latter is a
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multi-device system, controlled by a computer, dedicated to collect blood samples and
substitute the amount of blood received with an equal amount of normal saline (containing
NaCl 0.90% w/v). After each sampling session, samples were allowed to clot at room
temperature prior to centrifugation and serum was frozen at−80 ◦C until assayed. Analysis
was performed by an electrochemiluminescence immunoassay (Cobas®, Roche Diagnostics
Ltd., West Sussex, UK). Cross reactivity with 11-deoxycortisol was 4.1%.
4.4. Model Validation Strategy
The 24-h hormone profiles of 9 participants (6 healthy volunteers and 3 adrenal
insufficiency patients) were used to validate the model as follows: randomly, one of the
24-h profiles was initially used to formulate the equation describing the circulating plasma
cortisol concentration as a function of time. The 6 profiles from the healthy volunteer study
were subsequently used to refine the pharmacokinetic model through model parameter
estimations, optimisations and validation of the assumptions related to the absorption and
clearance of cortisol. Finally, we tested the accuracy of the model to replicate the data from
the two remaining 24-h profiles of the Pulses study (Figure 6).
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Figure 6. Strategy for devel ping and optimising the pharmacokinetic model, describing the subcutaneous delivery of
hydrocortisone (HC). (a) One of the 24-h cortisol profiles (blue diagram) was selected at random and used to formulate an
equation describing plasma cortisol dynamics. We assumed constant rates of HC absorption an cle rance and showed
that such an approach ca not simulate reality. Three different scenarios were subsequently tested, of whi only one was
finally elected. (b) The select d optimised scenario assumes varying rates of HC absorption and cl arance depending
on the dos magnitude and circulating cortisol levels, respectively. The six 3-h healthy volunteer profiles (b ue diagrams)
under different subcutane us doses of HC were us d to validate hese assumptions and confirm the reliabil ty of the model.
(c) Four plasma cortisol values from each of the remaining two patients with adrenocortical insufficiency were inputted
into the model to predict their whole 24-h hormonal profile (red diagram). (d) The (theoretical) output of the model (red
diagram) was compared to the actual 24-h plasma cortisol profile (blue diagram) of each of the two patients. HV: healthy
volunteers.
4.5. Description of Parameters
Table 1 describes all parameters and state variables used in this work.
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Table 1. Biomodelling Parameters.
Parameter Description Means of Estimation Units
C(t) Plasma cortisol concentrationas a function of time. Predicted by the model nmol/L
Sc(t)
Subcutaneous cortisol
concentration as a function of
time.





Cortisol absorption rate in
subcutaneous tissue. Real
positive number.
Initial value fitted to data 1/min
k(t) Plasma cortisol clearance rate.Real positive number. Initial value fitted to data 1/min
t Time Self-explanatory min
σ





Unit conversion factor for
concentration from mg to
nmol/L in plasma. Real
number, constant,
h = 106/(362.42 × `)
Self-explanatory nmol/mg
`





We based the formulation of the pharmacokinetic model on established biochemical
principles [22]. Our approach involves a two-compartment model of sub-cutaneous and
plasma GC dynamics. Starting from the simple assumption that GC absorption and
clearance rates are constant (Part 1, see below), we proceed to show how considering them
as variable improves the model predictive power (Parts 2 and 3, see below) (Figure 7). In all
model simulations, we assumed a constant plasma volume of 3.025 L [23]. All simulations
were produced using a computer program written in the C++ programming language.
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Fig re 7. n illustration of the reaso ing behind the two-compartment model. Hydrocortisone
(HC) is administered into the subcutaneous tissue where it is absorbed with a rate of kα. Then, it is
distributed via the bloodstream throughout the body, where it is cleared (by the liver and kidneys)
with a rate k as predicted by the model. Initially, we assumed that both absorption and clearance
rates were constant (part 1) and demonstrated why this is an unrealistic assumption. Following this,
we proceeded to estimate a different ordered pair (k, kα) for every three-hour interval. Then, we
concatenated the eight curves together to create a graph for a full day (part 2). Finally, we assumed
th t both rates change every minute (part 3), with the absorption rate depending on the magnitude
of the dose administered and clearance rate depending on circulating cortisol levels.
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4.6.1. Part 1
Initially, we assumed that both the rates of absorption and clearance are constant,







= −kC(t) + kaSc(t) (4)
where Sc(t) and C(t) are the cortisol concentration in subcutaneous tissue and plasma,
respectively. Both are measured in nmol/L. The rates of absorption and clearance are
symbolized with kα and k, respectively, and are considered constant.
Equation (3) is easily solvable, with
Sc(t) = De−kat (5)
where D stands for the delivered HC dose measured in mg.
Substituting Equation (5) in (4) leads to the single differential equation:
dC(t)
dt
+ kC(t) = kaDe−kat (6)








where σ denotes the initial cortisol measurement in plasma (σ = C(0)).
To predict the concentration of cortisol for an arbitrary number of sequential dosages,













where n is the number of dosages and h is a factor that converts the units of cortisol
concentration from mg to nmol/L. The function δi(t) is a step function selecting for the i-th
dose, with δi(t) = 1 if t ≥ ti and δi(t) = 0 if t < ti. The derivation of Equation (8) can be found
in Appendix D. Using Equation (8), we simulated HC replacement throughout an entire
day while keeping (k, kα) constant.
4.6.2. Part 2
Using Equation (8), we produced a solution curve for every 3-h interval, which was
fitted to the data by choosing different (k, kα) pairs for each curve. Then, we concatenated
the curves creating a fitted simulation with a duration of 24 h.
4.6.3. Part 3
In this part, we developed a more realistic model by introducing the following consid-
erations: (i) Although the absorption and clearance rates change over time, these changes
are discontinuous and hence the constant rate model can be a good approximation for
small intervals of time. (ii) The clearance rate k varies proportionally to the concentration
of cortisol in plasma. Furthermore, the assumption that better approximates the data is
to use the maximum value of k(t) of all the values that have been calculated until now as
shown below; which resets to its initial value k0 every 24 h at 12:00 noon (in other words,
k(t) can only increase, but not decrease, proportionally to C(t) until it resets every 24 h).
(iii) The rate of absorption (kα) depends on the moving boundary of a small sphere of liquid
created within the subcutaneous tissue following HC delivery (Figure 8).
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i r . he reasoning behind the assumptions regarding the absorption rate of subcutaneous
hydrocortisone (HC) administration. This rate depends on the subcutaneous dose magnitude, and
the within-subject change in absorption rate with time. HC is a lipophilic molecule; its diffusion is
hardly restricted by tissue membranes and thus can be assumed to be isotropic. Accordingly, we
used a sphere as an approximation of the shape and movement of hormonal molecules infused into
the subcutaneous tissue. Left: the higher the subcutaneous dose volume, the lower the absorption
rate kα (kα is inversely proportional to the cubic root of the dose volume). When a small dose is
administered by the pump cannula (e.g., 30 µL or 0.3 mg of HC) (a), the ratio of the area of the sphere
to its volume is approximately 2.4-times greater than when a 13-times larger dose is administered
(e.g., 400 µL or 4 mg of HC) (b). Therefore, the absorption rate drops to almost a similar degree
(from about 0.01 to about 0.004). When administered in high doses, an increased fat deposition of the
hormone could also contribute to dose-dependent changes in the absorption rate. Right: compared
to the state where the absorption rate was considered constant and independent of the dosage, our
assumption (of a dose-dependent kα) indicates that in lower doses, the absorption would be higher,
while in higher doses would be lower (c). Part of the Figure has been created with BioRender.com.
Based on consideration (ii), it follows that for K(t), a function such that K(t) = k0
C(t−1)
C(0)
for some initial concentration C(0) and for x ∈ R, the plasma cortisol clearance rate
is given by k(t) = max{K(x) : 0 < x ≤ t− 1} if t > 0 and k(t) = k0 if t = 0. Then, if
t = 1260 min (at 12:00 p.m.), k(t) = k0 (see also Appendix E). In relation to consideration (iii),
we hypothesized that a small spherical pressure region is created within the subcutaneous
tissue following the infusion of the HC solution [24–27].
The rate of absorption is dependent on the area of that receding sphere. Since the
absorption rate is calculated as a percentage of cortisol at a given time, we postulated the
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3 × ka(0) for some initial kα(0) and initial dosage D(0)
(see Appendix F).
Finally, based on our initial assumptions about kα being dependent on the moving
boundary of a small sphere, we estimated the volume in the subcutaneous tissue (see
Appendix G) for any given time. To make calculations easier, we did that by estimating it
once every minute.
A brute-force search algorithm checks the output of the model for different initial
pairs of (k0, kα0), to minimize the error with the four actual cortisol values given as input,
and then the whole 24-h curve is produced based on the chosen pair of (k0, kα0). Following
this, the pair of (k, kα) for every subsequent minute is calculated based on the algorithms
provided in Appendices E and G.
5. Conclusions
In this paper, we introduce a pharmacokinetic model that predicts the 24-h plasma
cortisol profile for patients with adrenocortical insufficiency under subcutaneous pulsatile
HC replacement with good accuracy (mean absolute percent error of 14%), especially when
only four plasma cortisol measurements are provided. This pharmacokinetic model can be
used to support clinical trials or practice involving subcutaneous HC delivery in patients
with reduced endogenous capacity to synthesize GCs.
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Appendix A
Figure A1 represents a comparison of the revised model predictions with plasma CORT
data, if calculation of the initial pair of (k, kα) is based on different sets of four CORT time
point measurements. The time distance between the four CORT measurements was retained
across the different calculations (t0, t0 + 30 min, t0 + 60 min, and t0 + 90 min), but each initial
time t0 was shifted by 3 h (black arrows and light blue frames). The data from the Pulses
study Subject 1 was used (see Materials and Methods). CORT: cortisol, k: clearance rate,
kα: absorption rate. Time points of delivery (magnitude of doses): 0 min (2.3 mg/230 µL),
180 min (2.3 mg/230 µL), 360 min (0.5 mg/50 µL), 540 min (0.5 mg/50 µL), 720 min
(4 mg/400 µL), 900 min (4 mg/400 µL), 1080 min (4 mg/400 µL), 1260 min (2.3 mg/230 µL).
The orange dots in the diagrams represent the actual plasma cortisol measurements (which
are the same in all cases), and the continuous lines (of varying colours) represent the model
predictions (which slightly change depending on the set of four CORT measurements,
which the calculations were based on).
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Appendix B 
Figure A2 represents a comparison of the revised model predictions with plasma 
CORT data, if calculation of the initial pair of (k, kα) is based other sets of four CORT meas-
urements, than those presented in Figure 4. For these calculations, the first CORT meas-
urement always corresponded to t0 = 0, but we changed the time distance of the remaining 
CORT measurements, being either short, long, or mixed (black dots in each diagram and 
blue frames). The data from the Pulses study Subject 1 was used (see Materials and Meth-
Figure A1. Comparison of the revised model predictions with plasma CORT data, if calculation of the initial pair of (k, kα)
was based on another set of four CORT time point measurements. The time distance between the four CORT measurements
was retained (t0, t0 + 30 min, t0 + 60 min, and t0 + 90 min), but each initial time t0 was shifted by 3 h (black arrows and light
blue frames). The data from the Pulses study Subject 1 was used (see Materials and Methods). CORT: cortisol, k: clearance
rate, kα: absorption rate. Time points of delivery (magnitude of doses): 0 min (2.3 mg/230 µL), 180 min (2.3 mg/230 µL),
360 min (0.5 mg/50 µL), 540 min (0.5 mg/50 µL), 720 min (4 mg/400 µL), 900 min (4 mg/400 µL), 1080 min (4 mg/400 µL),
1260 min (2.3 mg/230 µL). The orange dots in the diagrams represent the actual plasma cortisol measurements (which are
the same in all cases), and the continuous lines (of varying colours) represent the model predictions (which slightly change
depending on the set of four CORT measurements, which the calculations wer based on).
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Appendix B
Figure A2 represents a comparison of the revised model predictions with plasma
CORT data, if calculation of the initial pair of (k, kα) is based other sets of four CORT
measurements, than those presented in Figure 4. For these calculations, the first CORT
measurement always corresponded to t0 = 0, but we changed the time distance of the
remaining CORT measurements, being either short, long, or mixed (black dots in each
diagram and blue frames). The data from the Pulses study Subject 1 was used (see Materials
and Methods). CORT: cortisol, k: clearance rate, kα: absorption rate. Time points of
delivery (magnitude of doses): 0 min (2.3 mg/230 µL), 180 min (2.3 mg/230 µL), 360 min
(0.5 mg/50 µL), 540 min (0.5 mg/50 µL), 720 min (4 mg/400 µL), 900 min (4 mg/400 µL),
1080 min (4 mg/400 µL), 1260 min (2.3 mg/230 µL).
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Figure A2. Comparison of the revised model predictions with plasma CORT data, if calculation of the initial pair of (k,
kα) was based on another set of four CORT measurements. The first CORT measurement always corresponded to t0 = 0,
but we changed the time distance of the remaining CORT measurements, being either short, long, or mixed (black dots in
each diagram and blue frames). The data from the Pulses study Subject 1 was used (see Materials and Methods). CORT:
cortisol, k: clearance rate, α: absorption rate. Time oints of deliv ry (magnitude of doses): 0 min (2.3 mg/230 µL), 180 min
(2.3 mg/230 µL), 360 in (0.5 mg/50 µL), 540 in (0.5 mg/50 µL), 720 in (4 mg/40 µL), 9 0 in (4 mg/40 µL), 1080 min
(4 mg/400 µL), 1260 min (2.3 mg/230 µL).
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+ kC(s) = kaDe−kas (A1)





























where σ stands for the plasma cortisol concentration at time zero. This solution constitutes
Equation (7) of the main text.
Appendix D








This holds for a single dosage D. Then for two dosages (D1, D2) we obtain the
following:









where δ1(t) = 0 for t < t1 and 1 for t > t1, δ2(t) = 0 for t < t2 and 1 for t > t2, with t1 = 0 and
t2 = 180 min. Extrapolating from this, we can derive a formula for the cumulative effect of













where t1 = 0, t2 = 180 min, t3 = 360 min, etc.
Appendix E
To estimate k(t), we use the following algorithm:
Set k = k0, k0 constant.
For (t = 0, t ≤ tn, t++)




if K(t+1) > K(t)
k(t+1) = K(t+1)
else k(t+1) = K(t)
if t = 1260
k(t) = k0
Return k(t)
Where K(t) is an intermediate variable used to calculate k(t). The time t = 1260
(12:00 p.m.) is where the reset to the initial value happens. We assume a period of 24 h,
although for some profiles the resetting might take place at shorter time intervals. Our
Pharmaceutics 2021, 13, 769 17 of 19
model can accommodate shorter reset periods such as 12-h long periods, although we
present the 24-h period which best fits the data. It is worth noting that recent experimental
data support that hepatocytes do not have a constant catabolic capacity, but rather an
oscillating catabolic capacity, characterized by periods of 8, 12 or 24 h [28].
Appendix F
Based on the assumption that a small sphere of HC solution is created within the
subcutaneous tissue, it follows that the rate of absorption is dependent on the area of
that sphere. Since the rate is calculated as a percentage of cortisol at a given time, we can





where v̂ is assumed to be a constant.












Yet since r(t) is dependent on the remaining dosage Sc(t) (taking into consideration































Finally, based on our initial assumptions, we can estimate the volume of the assumed
sphere in the subcutaneous tissue at any time. To make calculations easier, we do that by
estimating it once every minute. The use of the symbol v̂ for the constant is deliberate.













× [length] = [length]
[time]
(A16)
ka(t) = 1[time] is a rate and r(t) is measured in units of length. Hence, we conclude that v̂ is a
unit of velocity. To understand this, we need to note that kα represents the probability that a
molecule belonging to the sphere within the subcutaneous tissue passes to the bloodstream
times the number of molecules belonging to the sphere, i.e., the rate at which molecules
pass from the subcutaneous tissue to the bloodstream. From a statistical mechanics point of
Pharmaceutics 2021, 13, 769 18 of 19
view, the kα rate can thus be interpreted as the group velocity v̂ of the molecules crossing
from one compartment to the other per unit length.
Appendix G
To estimate kα(t) we use the following algorithm:
Set Sc(0) = D
Set kα(0) = kα0
For (t = 0; t ≤ tn; t ++)
Sc(t + 1) = Sc(t)exp(−kα(t))
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